Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aldagen, Inc.
Aldea Pharmaceuticals will begin clinical trials in acute alcohol intoxication and Fanconi anemia for AD-6626, the company's lead drug candidate for aldehyde metabolism disorders, with $24m in Series B venture capital from new Russian and Chinese investors and existing US-based VC backers.
Cytomedix is to downsize its R&D activities in a renewed focus on profitability, in what is its second reorganization in as many months.
Cytomedix stock lost 25% of its value on 20 February when the Gaithersburg, Maryland-based company specializing in autologous regenerative therapies announced three different financing vehicles designed to generate up to $27.5 million for its "2013 operational business plan."
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.